NCT06193759 - Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 20, 2024

Primary Completion Date

December 29, 2030

Study Completion Date

December 29, 2032

Conditions

Medulloblastoma, ChildhoodAtypical Teratoid/Rhabdoid Tumor of CNSEmbryonal Tumor With Multilayered RosettesPineoblastomaEmbryonal Tumor of CNS

Interventions

BIOLOGICAL

Multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA)

Young patients with embryonal central nervous system (CNS) malignancies typically are unable to receive irradiation due to significant adverse effects and are treated with intensive chemotherapy followed by autologous stem cell rescue; however, despite intensive therapy, many of these patients relapse. In this study, individualized TSA-T cells will be generated against proteogenomically determined tumor-specific antigens after standard of care treatment in children less than 5 years of age with embryonal brain tumors.

Trial Locations (1)

20010

RECRUITING

Children's National Hospital, Washington D.C.